Year : 2012 | Volume
: 1 | Issue : 4 | Page : 171--175
Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?
Hakam Yaseen1, Maha Darwich2, Hossam Hamdy1
1 Department of Pediatric, University Hospital Sharjah, Sharjah, United Arab Emirates
2 Department of Pediatric, AL Falah Military Hospital, Sharjah, United Arab Emirates
Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening neonatal pathology resulting from poor hemodynamic and respiratory transition to extra uterine life. Inhaled nitric oxide (iNO) is a current, commonly used treatment of PPHN. However, iNO is not available therapy in many developing countries and around 50% of infants with PPHN do not respond to iNO therapy. Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. Recent studies have found that in PPHN, administration of Sildenafil was associated with a significant increase in the oxygenation and a reduction in mortality with no clinically important side effects.
Department of Pediatric, PO Box 25624, Sharjah
United Arab Emirates
|How to cite this article:|
Yaseen H, Darwich M, Hamdy H. Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?.J Clin Neonatol 2012;1:171-175
|How to cite this URL:|
Yaseen H, Darwich M, Hamdy H. Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?. J Clin Neonatol [serial online] 2012 [cited 2022 May 18 ];1:171-175
Available from: https://www.jcnonweb.com/article.asp?issn=2249-4847;year=2012;volume=1;issue=4;spage=171;epage=175;aulast=Yaseen;type=0